Scynexis (SCYX) Short term Debt (2013 - 2023)

Scynexis (SCYX) reported Short term Debt of $34.6 million for Q1 2023, up 371.47% quarter-over-quarter from $7.3 million in Q3 2018.

Scynexis (SCYX) Short term Debt (2013 - 2023) Analysis & Trends

Scynexis has reported Short term Debt for 5 years, with the latest figure at $34.6 million in Q1 2023.

For the quarter ending Q1 2023, Short term Debt changed N/A year-over-year to $34.6 million; the trailing twelve-month figure through Mar 2023 stood at $34.6 million (changed N/A YoY), and the FY2017 full-year result was $4.3 million, changed N/A from the prior year.
Short term Debt for Q1 2023 stood at $34.6 million, up from $7.3 million in the prior quarter.
The five-year high for Short term Debt was $34.6 million in Q1 2023, with the low at $34.6 million in Q1 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Teva Pharmaceutical Industries	39.72 Bn	35.98 Bn	1.97 Bn
2	Zoetis	34.61 Bn	32.67 Bn	1.62 Bn
3	United Therapeutics	24.07 Bn	21.91 Bn	648.10 Mn
4	Aurora Cannabis	16.98 Bn	16.91 Bn	33.43 Mn
5	Neurocrine Biosciences	16.64 Bn	15.32 Bn	800.70 Mn
6	Elanco Animal Health	12.19 Bn	11.76 Bn	785.00 Mn
7	Alkermes	7.37 Bn	6.86 Bn	-116.06 Mn
8	Hims & Hers Health	6.62 Bn	5.87 Bn	396.79 Mn
9	Lantheus Holdings	6.47 Bn	5.97 Bn	230.92 Mn
10	Scynexis	225.23 Mn	165.97 Mn	-

Download Data